Department of Neurosurgery, First Affiliated Hospital, Zhengzhou University, Zhengzhou, China.
Department of Neurosurgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Pathol Oncol Res. 2021 Sep 22;27:1609825. doi: 10.3389/pore.2021.1609825. eCollection 2021.
Glioma is the primary malignant tumor of the central nervous system and presents high mortality and disability rates under existing treatment measures. Thioredoxin domain-containing 12 (TXNDC12) has been shown to play an important role in various malignant tumors. Therefore, we explored the clinicopathological characteristics of TXNDC12 in glioma to bring to light new ideas in its treatment. We obtained data packages related to TXNDC12 expression status in gliomas from public databases. We analyzed glioma TXNDC12 expression and patient survival status and validated the above results using glioma specimens from our institution. Next, we analyzed the value of TXNDC12 in combination with 1p19q and isocitrate dehydrogenase (IDH) on the prognosis of glioma by regression model and receiver operating characteristic curve (ROC). Finally, we explored the function of related genes by GO analysis and KEGG analysis. Compared with normal brain tissue, the expression of TXNDC12 in glioma cells, regarding both mRNA and protein levels, was significantly upregulated. The survival time of patients with high-expression of TXNDC12 in glioma cells was shortened. In the World Health Organization pathological classification, IDH status, 1p19q status, and IDH combined with 1p19q subgroups, the expression of TXNDC12 increased with the deterioration of the above indicators. Tumor local immune analysis showed that the immune cell infiltration in TXNDC12 high-expressing glioma tissue increased, the tumor purity was reduced. GO and KEGG analyses indicated that TXNDC12 may be involved in the malignant prognosis of glioma through glycosylation and antigen processing and presentation. We showed that TXNDC12 is significantly highly expressed in gliomas. This high expression predicts the poor prognosis of glioma patients and is related to the gliomas' local immune microenvironment. As a tumor-related gene, TXNDC12 may be used as a new prognostic judgment molecule.
神经胶质瘤是中枢神经系统的原发性恶性肿瘤,在现有治疗措施下死亡率和致残率较高。硫氧还蛋白结构域包含蛋白 12(TXNDC12)在各种恶性肿瘤中发挥着重要作用。因此,我们探讨了 TXNDC12 在神经胶质瘤中的临床病理特征,以期为其治疗提供新思路。我们从公共数据库中获取了与 TXNDC12 在神经胶质瘤中表达状态相关的数据包。我们分析了神经胶质瘤 TXNDC12 的表达与患者生存状况,并使用本机构的神经胶质瘤标本对上述结果进行了验证。接下来,我们通过回归模型和受试者工作特征曲线(ROC)分析了 TXNDC12 与 1p19q 和异柠檬酸脱氢酶(IDH)联合对神经胶质瘤预后的价值。最后,我们通过 GO 分析和 KEGG 分析探讨了相关基因的功能。与正常脑组织相比,神经胶质瘤细胞中 TXNDC12 的表达(无论是在 mRNA 还是蛋白水平上)均显著上调。神经胶质瘤细胞中 TXNDC12 高表达的患者生存时间缩短。在世界卫生组织病理分类中,IDH 状态、1p19q 状态以及 IDH 联合 1p19q 亚组中,随着上述指标的恶化,TXNDC12 的表达增加。肿瘤局部免疫分析表明,TXNDC12 高表达的神经胶质瘤组织中免疫细胞浸润增加,肿瘤纯度降低。GO 和 KEGG 分析表明,TXNDC12 可能通过糖基化和抗原加工及呈递参与神经胶质瘤的恶性预后。我们发现 TXNDC12 在神经胶质瘤中显著高表达。这种高表达预示着神经胶质瘤患者的预后不良,且与神经胶质瘤的局部免疫微环境有关。作为一个肿瘤相关基因,TXNDC12 可能被用作新的预后判断分子。